These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28543084)

  • 1. Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.
    Li Y; Ramírez-Valle F; Xue Y; Ventura JI; Gouedard O; Mei J; Takeshita K; Palmisano M; Zhou S
    J Clin Pharmacol; 2017 Oct; 57(10):1279-1289. PubMed ID: 28543084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
    Larson RA; Yin OQ; Hochhaus A; Saglio G; Clark RE; Nakamae H; Gallagher NJ; Demirhan E; Hughes TP; Kantarjian HM; le Coutre PD
    Eur J Clin Pharmacol; 2012 May; 68(5):723-33. PubMed ID: 22207416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
    Brown JR; Harb WA; Hill BT; Gabrilove J; Sharman JP; Schreeder MT; Barr PM; Foran JM; Miller TP; Burger JA; Kelly KR; Mahadevan D; Ma S; Li Y; Pierce DW; Barnett E; Marine J; Miranda M; Azaryan A; Yu X; Nava-Parada P; Mei J; Kipps TJ
    Haematologica; 2016 Jul; 101(7):e295-8. PubMed ID: 27151992
    [No Abstract]   [Full Text] [Related]  

  • 6. Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
    Edlund H; Lee SK; Andrew MA; Slatter JG; Aksenov S; Al-Huniti N
    Clin Pharmacokinet; 2019 May; 58(5):659-672. PubMed ID: 30556110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.
    Evans EK; Tester R; Aslanian S; Karp R; Sheets M; Labenski MT; Witowski SR; Lounsbury H; Chaturvedi P; Mazdiyasni H; Zhu Z; Nacht M; Freed MI; Petter RC; Dubrovskiy A; Singh J; Westlin WF
    J Pharmacol Exp Ther; 2013 Aug; 346(2):219-28. PubMed ID: 23709115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 9. Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours.
    Fernandez-Teruel C; Cullberg M; Eberlein C; Barry ST; Zhou D
    Clin Pharmacokinet; 2024 Aug; 63(8):1191-1204. PubMed ID: 39127854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.
    Yu M; Gao Z; Dai X; Gong H; Zhang L; Chen X; Zhong DF; Sy SK
    Clin Pharmacokinet; 2017 Jan; 56(1):65-76. PubMed ID: 27379402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
    Yang S; Lukey P; Beerahee M; Hoke F
    Clin Pharmacokinet; 2013 Mar; 52(3):187-98. PubMed ID: 23254770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.
    Zhou X; Mould DR; Takubo T; Sheldon-Waniga E; Huebner D; Milton A; Venkatakrishnan K
    Br J Clin Pharmacol; 2018 Jan; 84(1):35-51. PubMed ID: 28891222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
    Ou YC; Liu L; Tariq B; Wang K; Jindal A; Tang Z; Gao Y; Sahasranaman S
    Clin Transl Sci; 2021 Mar; 14(2):764-772. PubMed ID: 33306268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
    Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.
    Dai G; Pfister M; Blackwood-Chirchir A; Roy A
    J Clin Pharmacol; 2008 Nov; 48(11):1254-69. PubMed ID: 18779376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
    Hughes JH; Phelps MA; Upton RN; Reuter SE; Gao Y; Byrd JC; Grever MR; Hofmeister CC; Marcucci G; Blum W; Blum KA; Foster DJR
    Br J Clin Pharmacol; 2019 May; 85(5):924-934. PubMed ID: 30672004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.